Insight into Investing in BSX – Analyst Perspectives

By Chris Stiles • Wednesday, September 10 15:30 • Permanent Link

Large-cap Health Care company Boston Scientific has moved -3.1% so far today on a volume of 7,177,894, compared to its average of 7,051,472. In contrast, the S&P 500 index moved 0.0%.

Boston Scientific trades -15.92% away from its average analyst target price of $124.53 per share. The 31 analysts following the stock have set target prices ranging from $99.0 to $140.0, and on average have given Boston Scientific a rating of buy.

If you are considering an investment in BSX, you'll want to know the following:

Boston Scientific's current price is 415.8% above its Graham number of $20.3, which implies that at its current valuation it does not offer a margin of safety
Boston Scientific has moved 30.3% over the last year, and the S&P 500 logged a change of 17.3%
Based on its trailing earnings per share of 1.68, Boston Scientific has a trailing 12 month Price to Earnings (P/E) ratio of 62.3 while the S&P 500 average is 29.3
BSX has a forward P/E ratio of 37.5 based on its forward 12 month price to earnings (EPS) of $2.79 per share
Its Price to Book (P/B) ratio is 6.91 compared to its sector average of 3.19
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Based in Marlborough, the company has 53,000 full time employees and a market cap of $155.15 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.